Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 11/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.41 |
| ▸ | F11 | P03951 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969023 | 0.94 | CSF1R (0.42) | CSF1RLPLLIPGF11F2 | |
| SCHEMBL1877988 | 0.86 | CSF1R (0.48) | CSF1RLPLLIPGF11CA1 | |
| SCHEMBL25203373 | 0.86 | CSF1R (0.48) | CSF1RLPLLIPGF11CA1 | |
| SCHEMBL17365883 | 0.84 | LPL (0.45) | CSF1RLPLLIPGF11F2 | |
| SCHEMBL21452293 | 0.84 | LPL (0.41) | CSF1RLPLLIPGF11F2 | |
| SCHEMBL21434075 | 0.84 | LPL (0.41) | CSF1RLPLLIPGF11F2 | |
| SCHEMBL31466224 | 0.84 | LPL (0.45) | CSF1RLPLLIPGF11F2 | |
| SCHEMBL23242451 | 0.84 | LPL (0.41) | CSF1RLPLLIPGF11F2 | |
| SCHEMBL15104513 | 0.84 | LPL (0.45) | CSF1RLPLLIPGF11F2 | |
| SCHEMBL31065382 | 0.83 | LIPE (0.39) | LPLLIPGF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MUTABILIS (FR) | 2019-05-28 | — | — | US | disclosed |
| EP-3110803-B1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2017-01-19 | — | — | US | disclosed |
| EP-3110803-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Mutabilis (FR) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128333-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LABORATOIRE BIODIM (FR) | 2015-09-03 | — | — | WO | disclosed |
| EP-2913330-A1 | Condensed derivatives of imidazole useful as pharmaceuticals | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | disclosed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | CSF1R 517/4885LPL 1105/4885LIPG 241/4885 |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MSR1, IFNAR1, NOD2 | CSF1R 2870/4885LPL 3929/4885LIPG 3409/4885 |
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MSR1, IFNAR1, NOD2 | CSF1R 2870/4885LPL 3929/4885LIPG 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.